{"title":"News","generated":"2026-11-09T22:20:00+00:00","page":0,"per_page":200,"total":222,"pages":2,"next":"https://www.anticancerfund.org/en/news.json?page=1","html_version":"https://www.anticancerfund.org/en/news","filterable_fields":["date"],"filter_values":"https://www.anticancerfund.org/en/llm-offramp/news__page_1/facets.json","usage":{"paging":"Add ?page=N to this URL, counting from 0, or follow the \"next\" link until it is absent.","filtering":"Every item carries its own date value, so filter this list locally. Do not request filtered variants of the human page: each one is a subset of what is already here. The possible values and their labels are listed under \"filter_values\", when present."},"items":[{"id":"499","entity_type":"node","label":"Falling through the cracks: why young cancer patients need specialised research and care","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/falling-through-cracks-why-young-cancer-patients-need-specialised-research-and-care","search_api_id":"entity:node/499:en","date":"2026-09-18"},{"id":"490","entity_type":"node","label":"The human side of a cancer diagnosis","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/human-side-cancer-diagnosis","search_api_id":"entity:node/490:en","date":"2026-05-22"},{"id":"488","entity_type":"node","label":"Podcast Gezondheid & Wetenschap","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/podcast-gezondheid-wetenschap","search_api_id":"entity:node/488:en","date":"2026-04-30"},{"id":"482","entity_type":"node","label":"Exercise as medicine: physical activity is vital before, during, and after cancer","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/exercise-medicine-physical-activity-vital-during-and-after-cancer","search_api_id":"entity:node/482:en","date":"2026-02-13"},{"id":"481","entity_type":"node","label":"Concentration of complex cancer care saves lives","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/concentration-complex-cancer-care-saves-lives","search_api_id":"entity:node/481:en","date":"2026-01-30"},{"id":"479","entity_type":"node","label":"Hot flush treatment has anti-breast cancer activity, study finds","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/hot-flush-treatment-has-anti-breast-cancer-activity-study-finds","search_api_id":"entity:node/479:en","date":"2026-01-05"},{"id":"477","entity_type":"node","label":"Breast cancer patients often receive unnecessary new cancer drugs","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/breast-cancer-patients-often-receive-unnecessary-new-cancer-drugs","search_api_id":"entity:node/477:en","date":"2025-12-19"},{"id":"475","entity_type":"node","label":"Pushing the boundaries of pancreatic cancer treatment","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/pushing-boundaries-pancreatic-cancer-treatment","search_api_id":"entity:node/475:en","date":"2025-12-18"},{"id":"474","entity_type":"node","label":"International collaboration secures over €11 million for rare cancer clinical trials","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/international-collaboration-secures-over-eu11-million-rare-cancer-clinical-trials","search_api_id":"entity:node/474:en","date":"2025-11-20"},{"id":"473","entity_type":"node","label":"Kanker zonder zever: Anticancer Fund exposes cancer myths in a new video series","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/kanker-zonder-zever-anticancer-fund-exposes-cancer-myths-new-video-series","search_api_id":"entity:node/473:en","date":"2025-11-13"},{"id":"472","entity_type":"node","label":"How lifestyle changes can support women with breast cancer","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/how-lifestyle-changes-can-support-women-breast-cancer","search_api_id":"entity:node/472:en","date":"2025-11-04"},{"id":"470","entity_type":"node","label":"Cancer patients misled by costly and unproven treatments abroad","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/cancer-patients-misled-costly-and-unproven-treatments-abroad","search_api_id":"entity:node/470:en","date":"2025-10-23"},{"id":"467","entity_type":"node","label":"First patient in EViDENCE BM trial to test personalised treatment for brain metastases","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/first-patient-evidence-bm-trial-test-personalised-treatment-brain-metastases","search_api_id":"entity:node/467:en","date":"2025-10-07"},{"id":"465","entity_type":"node","label":"De Warmste Week: lighting a flame for people living with invisible illness","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/de-warmste-week-lighting-flame-people-living-invisible-illness","search_api_id":"entity:node/465:en","date":"2025-09-30"},{"id":"463","entity_type":"node","label":"Pancreatic cancer: early results of PROSPER-trial with repurposed medication show potential to improve outcomes ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/pancreatic-cancer-early-results-prosper-trial-repurposed-medication-show-potential-improve","search_api_id":"entity:node/463:en","date":"2025-08-12"},{"id":"461","entity_type":"node","label":"Breaking new ground in bringing repurposed drugs to patients","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/breaking-new-ground-bringing-repurposed-drugs-patients","search_api_id":"entity:node/461:en","date":"2025-07-25"},{"id":"459","entity_type":"node","label":"Adaptive therapy shows promise in fighting drug-resistant cancer","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/adaptive-therapy-shows-promise-fighting-drug-resistant-cancer","search_api_id":"entity:node/459:en","date":"2025-07-15"},{"id":"454","entity_type":"node","label":"Joining a Europe-wide alliance to scale-up research on rare and hard-to-treat cancers","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/joining-europe-wide-alliance-scale-research-rare-and-hard-treat-cancers","search_api_id":"entity:node/454:en","date":"2025-06-03"},{"id":"453","entity_type":"node","label":"More than 1.000 patients participating in Anticancer Fund clinical trials ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/more-1000-patients-participating-anticancer-fund-clinical-trials","search_api_id":"entity:node/453:en","date":"2025-05-20"},{"id":"442","entity_type":"node","label":"New clinical trial targets aggressive brain tumours in children and young adults","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/new-clinical-trial-targets-aggressive-brain-tumours-children-and-young-adults","search_api_id":"entity:node/442:en","date":"2025-01-28"},{"id":"433","entity_type":"node","label":"Private cancer clinics under fire: Anticancer Fund and De Tijd expose shady treatments","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/private-cancer-clinics-under-fire-anticancer-fund-and-de-tijd-expose-shady-treatments","search_api_id":"entity:node/433:en","date":"2024-10-14"},{"id":"432","entity_type":"node","label":"National Lottery players support My Cancer Navigator, helping cancer patients get personalised information","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/national-lottery-players-support-my-cancer-navigator-helping-cancer-patients-get-personalised","search_api_id":"entity:node/432:en","date":"2024-10-03"},{"id":"427","entity_type":"node","label":"Survey: My Cancer Navigator boosts patient confidence and knowledge ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/survey-my-cancer-navigator-boosts-patient-confidence-and-knowledge","search_api_id":"entity:node/427:en","date":"2024-09-16"},{"id":"423","entity_type":"node","label":"My Cancer Navigator achieves crowdfunding goal and launches website","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/my-cancer-navigator-achieves-crowdfunding-goal-and-launches-website","search_api_id":"entity:node/423:en","date":"2024-07-19"},{"id":"420","entity_type":"node","label":"International call for research proposals on rare cancer drug development","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/international-call-research-proposals-rare-cancer-drug-development","search_api_id":"entity:node/420:en","date":"2024-06-25"},{"id":"430","entity_type":"node","label":"High-dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind placebo-controlled study (ViDMe trial)","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/high-dose-vitamin-d-supplementation-does-not-improve-outcome-cutaneous-melanoma-population","search_api_id":"entity:node/430:en","date":"2024-06-24"},{"id":"418","entity_type":"node","label":"Challenging the course of cancer - Annual Report 2023  ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/challenging-course-cancer-annual-report-2023","search_api_id":"entity:node/418:en","date":"2024-06-18"},{"id":"417","entity_type":"node","label":"Obtain a grant to develop your pancreatic cancer research idea","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/obtain-grant-develop-your-pancreatic-cancer-research-idea","search_api_id":"entity:node/417:en","date":"2024-06-13"},{"id":"413","entity_type":"node","label":"Pancreatic cancer: joint efforts with Pancreatic Cancer Europe for more therapies","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/pancreatic-cancer-joint-efforts-pancreatic-cancer-europe-more-therapies","search_api_id":"entity:node/413:en","date":"2024-05-28"},{"id":"412","entity_type":"node","label":"Exploring beta-blocker propranolol in angiosarcoma treatment","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/exploring-beta-blocker-propranolol-angiosarcoma-treatment","search_api_id":"entity:node/412:en","date":"2024-05-24"},{"id":"407","entity_type":"node","label":"#iDR24 - An international conference to move drug repurposing forward ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/idr24-international-conference-move-drug-repurposing-forward","search_api_id":"entity:node/407:en","date":"2024-03-05"},{"id":"406","entity_type":"node","label":"Childhood solid tumours: first results of paediatric Metro-PD1-study","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/childhood-solid-tumours-first-results-paediatric-metro-pd1-study","search_api_id":"entity:node/406:en","date":"2024-02-14"},{"id":"405","entity_type":"node","label":"World Cancer Day - unveiling the impact of My Cancer Navigator, a beacon for cancer patients ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/world-cancer-day-unveiling-impact-my-cancer-navigator-beacon-cancer-patients","search_api_id":"entity:node/405:en","date":"2024-02-02"},{"id":"404","entity_type":"node","label":"Rare cancer drug development boosted by international research alliance ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/rare-cancer-drug-development-boosted-international-research-alliance","search_api_id":"entity:node/404:en","date":"2024-01-18"},{"id":"403","entity_type":"node","label":"My Cancer Navigator featured in a podcast by Delphine Rémy ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/my-cancer-navigator-featured-podcast-delphine-remy","search_api_id":"entity:node/403:en","date":"2024-01-17"},{"id":"402","entity_type":"node","label":"Encouraging results from the AML-ViVA trial in Acute Myeloid Leukemia (AML) ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/encouraging-results-aml-viva-trial-acute-myeloid-leukemia-aml","search_api_id":"entity:node/402:en","date":"2023-12-14"},{"id":"401","entity_type":"node","label":"Breast cancer: initial trial results suggest new treatment combination for some patients ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/breast-cancer-initial-trial-results-suggest-new-treatment-combination-some-patients","search_api_id":"entity:node/401:en","date":"2023-12-06"},{"id":"399","entity_type":"node","label":"During Pancreatic Cancer Awareness Month, the Anticancer Fund redoubles its efforts","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/during-pancreatic-cancer-awareness-month-anticancer-fund-redoubles-its-efforts","search_api_id":"entity:node/399:en","date":"2023-11-07"},{"id":"398","entity_type":"node","label":"CTOS 2023: dedicated to improving outcomes for sarcoma patients","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/ctos-2023-dedicated-improving-outcomes-sarcoma-patients","search_api_id":"entity:node/398:en","date":"2023-10-27"},{"id":"397","entity_type":"node","label":"Empowering older adults with cancer: webinar on Shared decision-making","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/empowering-older-adults-cancer-webinar-shared-decision-making","search_api_id":"entity:node/397:en","date":"2023-09-15"},{"id":"396","entity_type":"node","label":"Young man with cancer inspires with resilience and generosity: Gilles Van der Spek’s remarkable fundraising efforts","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/young-man-cancer-inspires-resilience-and-generosity-gilles-van-der-speks-remarkable","search_api_id":"entity:node/396:en","date":"2023-09-07"},{"id":"395","entity_type":"node","label":"First patients for trial that investigates adaptive treatment for ovarian cancer","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/first-patients-trial-investigates-adaptive-treatment-ovarian-cancer","search_api_id":"entity:node/395:en","date":"2023-08-11"},{"id":"284","entity_type":"node","label":"Promising trial in pancreatic cancer enrols first patient","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/promising-trial-pancreatic-cancer-enrols-first-patient","search_api_id":"entity:node/284:en","date":"2023-04-25"},{"id":"285","entity_type":"node","label":"Why medicines regulators should start a 'Drug Evidence Watch' process","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/why-medicines-regulators-should-start-drug-evidence-watch-process","search_api_id":"entity:node/285:en","date":"2023-04-13"},{"id":"283","entity_type":"node","label":"We present ambitious recommendations for the EU pharmaceutical legislation","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/we-present-ambitious-recommendations-eu-pharmaceutical-legislation","search_api_id":"entity:node/283:en","date":"2023-03-16"},{"id":"282","entity_type":"node","label":"First patient in study to treat prostate cancer more personally with an on/off-strategy.","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/first-patient-study-treat-prostate-cancer-more-personally-onoff-strategy","search_api_id":"entity:node/282:en","date":"2023-03-06"},{"id":"281","entity_type":"node","label":"Our groundshot: better and longer lives for people with cancer ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/our-groundshot-better-and-longer-lives-people-cancer","search_api_id":"entity:node/281:en","date":"2023-02-28"},{"id":"280","entity_type":"node","label":"Ensuring completeness and timeliness of cancer treatment guidelines","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/ensuring-completeness-and-timeliness-cancer-treatment-guidelines","search_api_id":"entity:node/280:en","date":"2023-02-23"},{"id":"279","entity_type":"node","label":"Parents of children with cancer despair because treatments are lacking","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/parents-children-cancer-despair-because-treatments-are-lacking","search_api_id":"entity:node/279:en","date":"2023-02-15"},{"id":"278","entity_type":"node","label":"World Cancer Day: Closing the gap in cancer care ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/world-cancer-day-closing-gap-cancer-care","search_api_id":"entity:node/278:en","date":"2023-02-02"},{"id":"277","entity_type":"node","label":"Informed and Shared Decision-Making are cornerstones of patient-centred healthcare","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/informed-and-shared-decision-making-are-cornerstones-patient-centred-healthcare","search_api_id":"entity:node/277:en","date":"2022-12-15"},{"id":"276","entity_type":"node","label":"My Cancer Navigator is reinforced with the appointment of Annes Valckenaers","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/my-cancer-navigator-reinforced-appointment-annes-valckenaers","search_api_id":"entity:node/276:en","date":"2022-10-28"},{"id":"275","entity_type":"node","label":"PRIMMO-study shows poor response to combination treatment for women with cervical or endometrial cancer","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/primmo-study-shows-poor-response-combination-treatment-women-cervical-or-endometrial-cancer","search_api_id":"entity:node/275:en","date":"2022-10-25"},{"id":"272","entity_type":"node","label":"Drug repurposing as a potential source of innovative therapies in cervical cancer ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/drug-repurposing-potential-source-innovative-therapies-cervical-cancer","search_api_id":"entity:node/272:en","date":"2022-10-11"},{"id":"273","entity_type":"node","label":"We support an international call for research proposals in rare cancers","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/we-support-international-call-research-proposals-rare-cancers","search_api_id":"entity:node/273:en","date":"2022-10-11"},{"id":"271","entity_type":"node","label":"Pembrolizumab, radiotherapy, and an immunomodulatory five‑drug cocktail in pre-treated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/pembrolizumab-radiotherapy-and-immunomodulatory-five-drug-cocktail-pre-treated-patients","search_api_id":"entity:node/271:en","date":"2022-10-04"},{"id":"270","entity_type":"node","label":"We join hands to defeat neuroblastoma, a rare cancer that affects children ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/we-join-hands-defeat-neuroblastoma-rare-cancer-affects-children","search_api_id":"entity:node/270:en","date":"2022-10-03"},{"id":"269","entity_type":"node","label":"Patricia Vandamme joins the Anticancer Fund as Policy Officer ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/patricia-vandamme-joins-anticancer-fund-policy-officer","search_api_id":"entity:node/269:en","date":"2022-09-30"},{"id":"267","entity_type":"node","label":"We’re improving our information service for cancer patients","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/were-improving-our-information-service-cancer-patients","search_api_id":"entity:node/267:en","date":"2022-09-19"},{"id":"264","entity_type":"node","label":"‘The Art of Fearless Living’ - Charity Art Experience by Jean-Philippe Demeyer","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/art-fearless-living-charity-art-experience-jean-philippe-demeyer","search_api_id":"entity:node/264:en","date":"2022-09-02"},{"id":"266","entity_type":"node","label":"REMEDi4ALL launches to drive forward the repurposing of medicines in Europe","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/remedi4all-launches-drive-forward-repurposing-medicines-europe","search_api_id":"entity:node/266:en","date":"2022-09-01"},{"id":"265","entity_type":"node","label":"Kanaal Z stelt het Antikankerfonds gebald in 1 minuut voor","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/kanaal-z-stelt-het-antikankerfonds-gebald-1-minuut-voor","search_api_id":"entity:node/265:en","date":"2022-08-27"},{"id":"263","entity_type":"node","label":"Going the extra mile for people with pancreatic cancer","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/going-extra-mile-people-pancreatic-cancer","search_api_id":"entity:node/263:en","date":"2022-07-12"},{"id":"262","entity_type":"node","label":"The Anticancer Fund announces the appointment of Alice Dossche as member of the board","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/anticancer-fund-announces-appointment-alice-dossche-member-board","search_api_id":"entity:node/262:en","date":"2022-06-17"},{"id":"261","entity_type":"node","label":"Metzolimos metronomic cyclophosphamide (CP) and methotrexate (MTX) combined with zoledronic acid (ZA) and sirolimus (SIR) in patients with advanced solid tumor with bone metastasis and advanced pretreated osteosarcoma (OSS): A phase Ib study.","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/metzolimos-metronomic-cyclophosphamide-cp-and-methotrexate-mtx-combined-zoledronic-acid-za-and","search_api_id":"entity:node/261:en","date":"2022-06-13"},{"id":"260","entity_type":"node","label":"Affordable life-saving drugs are missed by cancer treatment guidelines","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/affordable-life-saving-drugs-are-missed-cancer-treatment-guidelines","search_api_id":"entity:node/260:en","date":"2022-05-25"},{"id":"259","entity_type":"node","label":"First patient for trial with promising repurposed drug in pancreatic cancer ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/first-patient-trial-promising-repurposed-drug-pancreatic-cancer","search_api_id":"entity:node/259:en","date":"2022-05-24"},{"id":"258","entity_type":"node","label":"'Entrepreneurs with a heart': stand up to cancer!","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/entrepreneurs-heart-stand-cancer","search_api_id":"entity:node/258:en","date":"2022-05-20"},{"id":"257","entity_type":"node","label":"Determinants  of  25-hydroxyvitamin  D  Status  in  a  Cutaneous  Melanoma Population - A substudy of the VidME trial ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/determinants-25-hydroxyvitamin-d-status-cutaneous-melanoma-population-substudy-vidme-trial","search_api_id":"entity:node/257:en","date":"2022-05-16"},{"id":"255","entity_type":"node","label":"The Anticancer Fund announces the appointment of new board members","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/anticancer-fund-announces-appointment-new-board-members","search_api_id":"entity:node/255:en","date":"2022-04-01"},{"id":"253","entity_type":"node","label":"3 Belgian cancer organisations join forces","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/3-belgian-cancer-organisations-join-forces","search_api_id":"entity:node/253:en","date":"2022-02-22"},{"id":"252","entity_type":"node","label":"Thinking outside the box – Annual Report 2021","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/thinking-outside-box-annual-report-2021","search_api_id":"entity:node/252:en","date":"2022-02-17"},{"id":"251","entity_type":"node","label":"How could patients with brain metastases live longer?","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/how-could-patients-brain-metastases-live-longer","search_api_id":"entity:node/251:en","date":"2022-02-08"},{"id":"250","entity_type":"node","label":"World Cancer Day is a moment of action","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/world-cancer-day-moment-action","search_api_id":"entity:node/250:en","date":"2022-02-04"},{"id":"249","entity_type":"node","label":"My Cancer Navigator, because cancer concerns us all ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/my-cancer-navigator-because-cancer-concerns-us-all","search_api_id":"entity:node/249:en","date":"2022-01-28"},{"id":"246","entity_type":"node","label":"How to capture real-world data to prove efficacy of repurposed drugs? ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/how-capture-real-world-data-prove-efficacy-repurposed-drugs","search_api_id":"entity:node/246:en","date":"2021-11-15"},{"id":"247","entity_type":"node","label":"Drug Repurposing as a Source of Innovative Therapies in Cervical Cancer","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/drug-repurposing-source-innovative-therapies-cervical-cancer","search_api_id":"entity:node/247:en","date":"2021-11-15"},{"id":"244","entity_type":"node","label":"Clinical research in surgical oncology matters","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/clinical-research-surgical-oncology-matters","search_api_id":"entity:node/244:en","date":"2021-11-08"},{"id":"245","entity_type":"node","label":"METRO-PD1: A Phase I Feasibility Study Evaluating Anti-PD1 (NIVOLUMAB) In Combination With Metronomic Chemotherapy In Children And Teenagers With Refractory/Relapsing Solid Tumors Or Lymphoma","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/metro-pd1-phase-i-feasibility-study-evaluating-anti-pd1-nivolumab-combination-metronomic","search_api_id":"entity:node/245:en","date":"2021-11-08"},{"id":"243","entity_type":"node","label":"The Anticancer Fund is participating in the World Cancer Series organised by The Economist","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/anticancer-fund-participating-world-cancer-series-organised-economist","search_api_id":"entity:node/243:en","date":"2021-11-02"},{"id":"241","entity_type":"node","label":"Our good cause My Cancer Navigator now supported by Belfius","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/our-good-cause-my-cancer-navigator-now-supported-belfius","search_api_id":"entity:node/241:en","date":"2021-10-29"},{"id":"240","entity_type":"node","label":"Drug repurposing candidates in the treatment of brain metastases","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/drug-repurposing-candidates-treatment-brain-metastases","search_api_id":"entity:node/240:en","date":"2021-09-30"},{"id":"237","entity_type":"node","label":"10 drugs in 1 trial: an unconventional way to fight brain cancer ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/10-drugs-1-trial-unconventional-way-fight-brain-cancer","search_api_id":"entity:node/237:en","date":"2021-09-07"},{"id":"236","entity_type":"node","label":"A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/phase-ibiia-trial-9-repurposed-drugs-combined-temozolomide-treatment-recurrent-glioblastoma","search_api_id":"entity:node/236:en","date":"2021-09-06"},{"id":"234","entity_type":"node","label":"Discovery and 3D imaging of a novel ΔNp63- expressing basal cell type in human pancreatic ducts with implications in disease","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/discovery-and-3d-imaging-novel-dnp63-expressing-basal-cell-type-human-pancreatic-ducts","search_api_id":"entity:node/234:en","date":"2021-08-10"},{"id":"233","entity_type":"node","label":"Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/use-non-cancer-drugs-and-survival-among-patients-pancreatic-adenocarcinoma-nationwide-registry","search_api_id":"entity:node/233:en","date":"2021-08-06"},{"id":"232","entity_type":"node","label":"WHO endorses drug repurposing strategy of the Anticancer Fund","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/who-endorses-drug-repurposing-strategy-anticancer-fund","search_api_id":"entity:node/232:en","date":"2021-07-30"},{"id":"230","entity_type":"node","label":"First patient for EORTC-trial in oligometastatic rare cancers ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/first-patient-eortc-trial-oligometastatic-rare-cancers","search_api_id":"entity:node/230:en","date":"2021-07-02"},{"id":"228","entity_type":"node","label":"Trends in International Cancer Research Investment 2006-2018","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/trends-international-cancer-research-investment-2006-2018","search_api_id":"entity:node/228:en","date":"2021-06-18"},{"id":"224","entity_type":"node","label":"Honorary association for Gauthier Bouche with University College London","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/honorary-association-gauthier-bouche-university-college-london","search_api_id":"entity:node/224:en","date":"2021-05-21"},{"id":"217","entity_type":"node","label":"Second step in trial for children with solid cancers","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/second-step-trial-children-solid-cancers","search_api_id":"entity:node/217:en","date":"2021-05-17"},{"id":"226","entity_type":"node","label":"Repurposing Infectious Diseases Vaccines Against Cancer","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/repurposing-infectious-diseases-vaccines-against-cancer","search_api_id":"entity:node/226:en","date":"2021-05-13"},{"id":"231","entity_type":"node","label":"Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/exploring-new-uses-existing-drugs-innovative-mechanisms-fund-independent-clinical-research","search_api_id":"entity:node/231:en","date":"2021-05-04"},{"id":"222","entity_type":"node","label":"Diffuse intrinsic pontine glioma: a clinic in Mexico, social media, and unpublishable data","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/diffuse-intrinsic-pontine-glioma-clinic-mexico-social-media-and-unpublishable-data","search_api_id":"entity:node/222:en","date":"2021-05-01"},{"id":"212","entity_type":"node","label":"How to optimize cancer research for the benefit of the patient?","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/how-optimize-cancer-research-benefit-patient","search_api_id":"entity:node/212:en","date":"2021-03-30"},{"id":"219","entity_type":"node","label":"A prospective phase II, randomised multi-center trial of a biomodulatory treatment with metronomic low-dose treosulfan, pioglitazone and clarithromycin versus nivolumab in patients with lung cancer, after platin failure (ModuLung).","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/prospective-phase-ii-randomised-multi-center-trial-biomodulatory-treatment-metronomic-low-dose","search_api_id":"entity:node/219:en","date":"2021-03-16"},{"id":"211","entity_type":"node","label":"An Open Access Database of Licensed Cancer Drugs","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/open-access-database-licensed-cancer-drugs","search_api_id":"entity:node/211:en","date":"2021-03-11"},{"id":"216","entity_type":"node","label":"The European Union and personalised cancer medicine","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/european-union-and-personalised-cancer-medicine","search_api_id":"entity:node/216:en","date":"2021-03-08"},{"id":"210","entity_type":"node","label":"From lab to life: transforming childhood, adolescent and rare cancer care","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/lab-life-transforming-childhood-adolescent-and-rare-cancer-care","search_api_id":"entity:node/210:en","date":"2021-03-01"},{"id":"209","entity_type":"node","label":"Discover our Annual Report 2020","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/discover-our-annual-report-2020","search_api_id":"entity:node/209:en","date":"2021-02-15"},{"id":"206","entity_type":"node","label":"World Cancer Day - Because every patient deserves optimal treatment","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/world-cancer-day-because-every-patient-deserves-optimal-treatment","search_api_id":"entity:node/206:en","date":"2021-02-04"},{"id":"205","entity_type":"node","label":"The Anticancer Fund supports EORTC trial in oligometastatic rare cancers with Rising Tide Foundation","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/anticancer-fund-supports-eortc-trial-oligometastatic-rare-cancers-rising-tide-foundation","search_api_id":"entity:node/205:en","date":"2021-02-02"},{"id":"192","entity_type":"node","label":"First patient in EORTC's trial for retroperitoneal sarcoma","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/first-patient-eortcs-trial-retroperitoneal-sarcoma","search_api_id":"entity:node/192:en","date":"2021-01-21"},{"id":"204","entity_type":"node","label":"Study in pancreatic cancer improved survival rate of mice","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/study-pancreatic-cancer-improved-survival-rate-mice","search_api_id":"entity:node/204:en","date":"2021-01-08"},{"id":"220","entity_type":"node","label":"Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/potential-therapeutic-effect-low-dose-paclitaxel-melanoma-patients-resistant-immune-checkpoint","search_api_id":"entity:node/220:en","date":"2020-12-28"},{"id":"203","entity_type":"node","label":"The MATAO trial for ovarian cancer patients is open for participation","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/matao-trial-ovarian-cancer-patients-open-participation","search_api_id":"entity:node/203:en","date":"2020-12-11"},{"id":"199","entity_type":"node","label":"Discovering Darwin in oncology: Launch of a ‘Request for Application’ for researchers in evolutionary therapy ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/discovering-darwin-oncology-launch-request-application-researchers-evolutionary-therapy","search_api_id":"entity:node/199:en","date":"2020-12-01"},{"id":"191","entity_type":"node","label":"Finding existing drugs potentially active against BRCA mutated breast cancers: a literature based approach","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/finding-existing-drugs-potentially-active-against-brca-mutated-breast-cancers-literature-based","search_api_id":"entity:node/191:en","date":"2020-10-02"},{"id":"197","entity_type":"node","label":"Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/nicotinamide-combined-gemcitabine-immunomodulatory-therapy-restrains-pancreatic-cancer-mice","search_api_id":"entity:node/197:en","date":"2020-09-29"},{"id":"215","entity_type":"node","label":"ReDIReCT - Repurposing of Drugs: Innovative Revision of Cancer Treatment","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/redirect-repurposing-drugs-innovative-revision-cancer-treatment","search_api_id":"entity:node/215:en","date":"2020-09-24"},{"id":"189","entity_type":"node","label":"PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma—a proof of principle study","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/propangio-study-protocol-neoadjuvant-trial-efficacy-propranolol-monotherapy-cutaneous","search_api_id":"entity:node/189:en","date":"2020-09-18"},{"id":"188","entity_type":"node","label":"Comprehensive book on drug repurposing and cancer therapy","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/comprehensive-book-drug-repurposing-and-cancer-therapy","search_api_id":"entity:node/188:en","date":"2020-09-15"},{"id":"198","entity_type":"node","label":"Pancreatic resection with perioperative drug repurposing of propranolol and etodolac: trial protocol of the phase-II randomised placebo controlled PROSPER trial","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/pancreatic-resection-perioperative-drug-repurposing-propranolol-and-etodolac-trial-protocol","search_api_id":"entity:node/198:en","date":"2020-08-28"},{"id":"196","entity_type":"node","label":"Predicting combinations of immunomodulators to enhance dendritic cell-based vaccination based on a hybrid experimental and computational platform","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/predicting-combinations-immunomodulators-enhance-dendritic-cell-based-vaccination-based-hybrid","search_api_id":"entity:node/196:en","date":"2020-08-08"},{"id":"187","entity_type":"node","label":"\"Strengthening Europe in the fight against cancer\"","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/strengthening-europe-fight-against-cancer","search_api_id":"entity:node/187:en","date":"2020-08-04"},{"id":"184","entity_type":"node","label":"Repurposing of drugs for triple negative breast cancer: an overview","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/repurposing-drugs-triple-negative-breast-cancer-overview","search_api_id":"entity:node/184:en","date":"2020-07-14"},{"id":"185","entity_type":"node","label":"Reflection on Europe's Cancer Mission Board","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/reflection-europes-cancer-mission-board","search_api_id":"entity:node/185:en","date":"2020-07-10"},{"id":"186","entity_type":"node","label":"Our response to the European Commission's public consultation on the Pharmaceutical Strategy Roadmap","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/our-response-european-commissions-public-consultation-pharmaceutical-strategy-roadmap","search_api_id":"entity:node/186:en","date":"2020-07-07"},{"id":"180","entity_type":"node","label":"Follow-up: Webinar on drug repurposing for cancer in the COVID-19 era","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/follow-webinar-drug-repurposing-cancer-covid-19-era","search_api_id":"entity:node/180:en","date":"2020-06-29"},{"id":"178","entity_type":"node","label":"The Anticancer Fund is one of the first philanthropic organisations to join the European Cancer Community 365","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/anticancer-fund-one-first-philanthropic-organisations-join-european-cancer-community-365","search_api_id":"entity:node/178:en","date":"2020-06-15"},{"id":"177","entity_type":"node","label":"Webinar on drug repurposing for cancer in the COVID-19 area","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/webinar-drug-repurposing-cancer-covid-19-area","search_api_id":"entity:node/177:en","date":"2020-06-05"},{"id":"175","entity_type":"node","label":"Discover our strategic goals for 2020-2025 ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/discover-our-strategic-goals-2020-2025","search_api_id":"entity:node/175:en","date":"2020-05-25"},{"id":"172","entity_type":"node","label":"The Anticancer Fund supports EORTC trial in retroperitoneal sarcoma, a rare and aggressive cancer","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/anticancer-fund-supports-eortc-trial-retroperitoneal-sarcoma-rare-and-aggressive-cancer","search_api_id":"entity:node/172:en","date":"2020-04-28"},{"id":"173","entity_type":"node","label":"The Anticancer Fund welcomes new members in the Advisory Board","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/anticancer-fund-welcomes-new-members-advisory-board","search_api_id":"entity:node/173:en","date":"2020-04-27"},{"id":"171","entity_type":"node","label":"Adoptive T cell therapy beneficial for metastatic melanoma patients that did not respond to standard of care immune therapy.","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/adoptive-t-cell-therapy-beneficial-metastatic-melanoma-patients-did-not-respond-standard-care","search_api_id":"entity:node/171:en","date":"2020-04-23"},{"id":"170","entity_type":"node","label":"More than 200 trials to fight COVID-19 worldwide","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/more-200-trials-fight-covid-19-worldwide","search_api_id":"entity:node/170:en","date":"2020-04-07"},{"id":"169","entity_type":"node","label":"First patient in PropAngio-trial for angiosarcoma ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/first-patient-propangio-trial-angiosarcoma","search_api_id":"entity:node/169:en","date":"2020-03-30"},{"id":"183","entity_type":"node","label":"CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infltrating lymphocytes in ovarian cancer","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/ctla-4-blockade-boosts-expansion-tumor-reactive-cd8-tumor-infltrating-lymphocytes-ovarian","search_api_id":"entity:node/183:en","date":"2020-03-03"},{"id":"176","entity_type":"node","label":"Feedback on Europe's Beating Cancer Plan","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/feedback-europes-beating-cancer-plan","search_api_id":"entity:node/176:en","date":"2020-02-27"},{"id":"164","entity_type":"node","label":"Discover our Annual Impact Sheet 2019","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/discover-our-annual-impact-sheet-2019","search_api_id":"entity:node/164:en","date":"2020-02-24"},{"id":"162","entity_type":"node","label":"How to teach an old medicine new tricks","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/how-teach-old-medicine-new-tricks","search_api_id":"entity:node/162:en","date":"2020-02-18"},{"id":"163","entity_type":"node","label":"Challenges and opportunities for cancer clinical trials in low- and middle-income countries","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/challenges-and-opportunities-cancer-clinical-trials-low-and-middle-income-countries","search_api_id":"entity:node/163:en","date":"2020-02-18"},{"id":"159","entity_type":"node","label":"Cancer knows no boundaries, and neither do we","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/cancer-knows-no-boundaries-and-neither-do-we","search_api_id":"entity:node/159:en","date":"2020-02-04"},{"id":"160","entity_type":"node","label":"Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/nitroglycerin-radiosensitizer-non-small-cell-lung-cancer-results-prospective-imaging-based","search_api_id":"entity:node/160:en","date":"2020-02-03"},{"id":"161","entity_type":"node","label":"On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/label-or-label-overcoming-regulatory-and-financial-barriers-bring-repurposed-medicines-cancer","search_api_id":"entity:node/161:en","date":"2020-02-03"},{"id":"158","entity_type":"node","label":"Transparancy of clinical trial reports assured","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/transparancy-clinical-trial-reports-assured","search_api_id":"entity:node/158:en","date":"2020-01-22"},{"id":"157","entity_type":"node","label":"Clinical trials should remain transparent","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/clinical-trials-should-remain-transparent","search_api_id":"entity:node/157:en","date":"2020-01-21"},{"id":"156","entity_type":"node","label":"Biased by design? Clinical trials and patient benefit in oncology","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/biased-design-clinical-trials-and-patient-benefit-oncology","search_api_id":"entity:node/156:en","date":"2020-01-14"},{"id":"174","entity_type":"node","label":"The Anticancer Fund’s recommendations to Horizon Europe","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/anticancer-funds-recommendations-horizon-europe","search_api_id":"entity:node/174:en","date":"2019-12-18"},{"id":"154","entity_type":"node","label":"Launch of a Call for Research Proposal","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/launch-call-research-proposal","search_api_id":"entity:node/154:en","date":"2019-12-17"},{"id":"153","entity_type":"node","label":"Low-dose azacytidine, pioglitazone and retinoic acid in ≥ 60 years patients with acute myeloid leukaemia refractory to chemotherapy (AML-ViVA)","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/low-dose-azacytidine-pioglitazone-and-retinoic-acid-60-years-patients-acute-myeloid-leukaemia","search_api_id":"entity:node/153:en","date":"2019-12-09"},{"id":"152","entity_type":"node","label":"Intraoperative ketorolac in High-Risk Breast Cancer Patients. A Prospective, Randomized, Placebo-Controlled Clinical Trial.","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/intraoperative-ketorolac-high-risk-breast-cancer-patients-prospective-randomized-placebo","search_api_id":"entity:node/152:en","date":"2019-12-05"},{"id":"150","entity_type":"node","label":"More than 300 existing drugs have anticancer effects","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/more-300-existing-drugs-have-anticancer-effects","search_api_id":"entity:node/150:en","date":"2019-11-14"},{"id":"148","entity_type":"node","label":"Cancer patients should be aware of scientific misinformation","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/cancer-patients-should-be-aware-scientific-misinformation","search_api_id":"entity:node/148:en","date":"2019-11-05"},{"id":"149","entity_type":"node","label":"Journal retractions in oncology: a bibliometric study","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/journal-retractions-oncology-bibliometric-study","search_api_id":"entity:node/149:en","date":"2019-11-05"},{"id":"151","entity_type":"node","label":"Phase I Study of Fluvastatin/Celecoxib Combination in Children with Relapsing or Refractory Low or High Grade Glioma - First Results","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/phase-i-study-fluvastatincelecoxib-combination-children-relapsing-or-refractory-low-or-high","search_api_id":"entity:node/151:en","date":"2019-10-26"},{"id":"147","entity_type":"node","label":"Lung Cancer Survival Gains: Contributions of Academia and Industry","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/lung-cancer-survival-gains-contributions-academia-and-industry","search_api_id":"entity:node/147:en","date":"2019-09-30"},{"id":"145","entity_type":"node","label":"Pioglitazone and clarithromycin combined with metronomic chemotherapy vs. nivolumab in patients with advanced non-small-cell lung cancer: Outcomes from a randomized phase II trial (ModuLung)","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/pioglitazone-and-clarithromycin-combined-metronomic-chemotherapy-vs-nivolumab-patients","search_api_id":"entity:node/145:en","date":"2019-09-28"},{"id":"143","entity_type":"node","label":"Approaches to Advance Cancer Vaccines to Clinical Utility","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/approaches-advance-cancer-vaccines-clinical-utility","search_api_id":"entity:node/143:en","date":"2019-08-28"},{"id":"142","entity_type":"node","label":"Lydie Meheus appointed to EMA’s Committee for Advanced Therapies (CAT)","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/lydie-meheus-appointed-emas-committee-advanced-therapies-cat","search_api_id":"entity:node/142:en","date":"2019-07-30"},{"id":"144","entity_type":"node","label":"Drug Repurposing","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/drug-repurposing","search_api_id":"entity:node/144:en","date":"2019-07-03"},{"id":"141","entity_type":"node","label":"More than 30 clinical studies requested our funding","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/more-30-clinical-studies-requested-our-funding","search_api_id":"entity:node/141:en","date":"2019-06-27"},{"id":"140","entity_type":"node","label":"Saar Sinnaeve Communication Manager at the Anticancer Fund","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/saar-sinnaeve-communication-manager-anticancer-fund","search_api_id":"entity:node/140:en","date":"2019-06-03"},{"id":"179","entity_type":"node","label":"PRIMMO Study Protocol: A Phase II Study Combining PD-1 Blockade, Radiation and Immunomodulation to Tackle Cervical and Uterine Cancer","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/primmo-study-protocol-phase-ii-study-combining-pd-1-blockade-radiation-and-immunomodulation","search_api_id":"entity:node/179:en","date":"2019-05-28"},{"id":"139","entity_type":"node","label":"Perioperative therapies - Using repurposed drugs to improve cancer surgery outcomes","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/perioperative-therapies-using-repurposed-drugs-improve-cancer-surgery-outcomes","search_api_id":"entity:node/139:en","date":"2019-04-10"},{"id":"138","entity_type":"node","label":"Launch of the Anticancer Fund European Elections Manifesto 2019","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/launch-anticancer-fund-european-elections-manifesto-2019","search_api_id":"entity:node/138:en","date":"2019-04-09"},{"id":"194","entity_type":"node","label":"Evidence of β-blockers drug repurposing for the treatment of triple negative breast cancer: A systematic review.","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/evidence-b-blockers-drug-repurposing-treatment-triple-negative-breast-cancer-systematic-review","search_api_id":"entity:node/194:en","date":"2019-03-28"},{"id":"136","entity_type":"node","label":"Annual Impact Sheet 2018 published!","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/annual-impact-sheet-2018-published","search_api_id":"entity:node/136:en","date":"2019-03-18"},{"id":"181","entity_type":"node","label":"Tumour-reactive T cell subsets in the microenvironment of ovarian cancer","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/tumour-reactive-t-cell-subsets-microenvironment-ovarian-cancer","search_api_id":"entity:node/181:en","date":"2019-02-05"},{"id":"134","entity_type":"node","label":"A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/phase-2-study-assess-immunomodulatory-capacity-lecithin-based-delivery-system-curcumin","search_api_id":"entity:node/134:en","date":"2019-01-11"},{"id":"133","entity_type":"node","label":"The Anticancer Fund becomes a Public Utility Foundation","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/anticancer-fund-becomes-public-utility-foundation","search_api_id":"entity:node/133:en","date":"2018-12-18"},{"id":"129","entity_type":"node","label":"ReDO_DB: the repurposing drugs in oncology database","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/redodb-repurposing-drugs-oncology-database","search_api_id":"entity:node/129:en","date":"2018-12-06"},{"id":"127","entity_type":"node","label":"Intraoperative ketorolac in high-risk breast cancer patients with and without inflammation","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/intraoperative-ketorolac-high-risk-breast-cancer-patients-and-without-inflammation","search_api_id":"entity:node/127:en","date":"2018-12-05"},{"id":"128","entity_type":"node","label":"KETOROLAC poster presented at the San Antonio Breast Cancer Symposium","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/ketorolac-poster-presented-san-antonio-breast-cancer-symposium","search_api_id":"entity:node/128:en","date":"2018-12-05"},{"id":"122","entity_type":"node","label":"Positive preliminary results for innovative treatment against killer brain cancer glioblastoma.","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/positive-preliminary-results-innovative-treatment-against-killer-brain-cancer-glioblastoma","search_api_id":"entity:node/122:en","date":"2018-11-20"},{"id":"123","entity_type":"node","label":"Drug Repurposing as a Source of Innovative Therapies in Chondrosarcoma","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/drug-repurposing-source-innovative-therapies-chondrosarcoma","search_api_id":"entity:node/123:en","date":"2018-11-15"},{"id":"124","entity_type":"node","label":"Multi-arm Trial in Localized Osteosarcoma: Moving from a Dream to Reality","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/multi-arm-trial-localized-osteosarcoma-moving-dream-reality","search_api_id":"entity:node/124:en","date":"2018-11-15"},{"id":"182","entity_type":"node","label":"Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes in Patients With Metastatic Ovarian Cancer: A Pilot Study","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/adoptive-cell-therapy-tumor-infiltrating-lymphocytes-patients-metastatic-ovarian-cancer-pilot","search_api_id":"entity:node/182:en","date":"2018-09-26"},{"id":"118","entity_type":"node","label":"Adding 5 immunomodulators to radio- and immunotherapy without further increasing financial toxicity","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/adding-5-immunomodulators-radio-and-immunotherapy-without-further-increasing-financial","search_api_id":"entity:node/118:en","date":"2018-09-20"},{"id":"119","entity_type":"node","label":"International Conference on Immunotherapy Radiotherapy Combinations","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/international-conference-immunotherapy-radiotherapy-combinations","search_api_id":"entity:node/119:en","date":"2018-09-20"},{"id":"117","entity_type":"node","label":"My Cancer Navigator: pilot project for cancer patients ","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/my-cancer-navigator-pilot-project-cancer-patients","search_api_id":"entity:node/117:en","date":"2018-09-17"},{"id":"114","entity_type":"node","label":"Approval of pancreatic cancer trial with perioperative use of β-blocker and anti-inflammatory drug","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/approval-pancreatic-cancer-trial-perioperative-use-b-blocker-and-anti-inflammatory-drug","search_api_id":"entity:node/114:en","date":"2018-09-07"},{"id":"408","entity_type":"node","label":"Anonymous donor funds almost € 400.000 for pancreatic cancer trial","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/anonymous-donor-funds-almost-eu-400000-pancreatic-cancer-trial","search_api_id":"entity:node/408:en","date":"2018-09-07"},{"id":"113","entity_type":"node","label":"Almost 1000 hours of cancer questions: PIT facts & figures","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/almost-1000-hours-cancer-questions-pit-facts-figures","search_api_id":"entity:node/113:en","date":"2018-08-24"},{"id":"110","entity_type":"node","label":"Omics-driven drug repurposing in rare cancers","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/omics-driven-drug-repurposing-rare-cancers","search_api_id":"entity:node/110:en","date":"2018-07-24"},{"id":"112","entity_type":"node","label":"Zoom in: ACF for patients","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/zoom-acf-patients-0","search_api_id":"entity:node/112:en","date":"2018-07-20"},{"id":"109","entity_type":"node","label":"Zoom in: ACF for patients","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/zoom-acf-patients","search_api_id":"entity:node/109:en","date":"2018-07-16"},{"id":"107","entity_type":"node","label":"Guy Buyens becomes new medical director of the Anticancer Fund","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/guy-buyens-becomes-new-medical-director-anticancer-fund","search_api_id":"entity:node/107:en","date":"2018-07-04"},{"id":"104","entity_type":"node","label":"New uses for old drugs","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/new-uses-old-drugs","search_api_id":"entity:node/104:en","date":"2018-06-26"},{"id":"103","entity_type":"node","label":"Propranolol and breast cancer—a work in progress","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/propranolol-and-breast-cancer-work-progress","search_api_id":"entity:node/103:en","date":"2018-06-18"},{"id":"102","entity_type":"node","label":"“Hard” Drug Repurposing for Precision Oncology: The Missing Link?","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/hard-drug-repurposing-precision-oncology-missing-link","search_api_id":"entity:node/102:en","date":"2018-06-14"},{"id":"96","entity_type":"node","label":"Uppsala Health Summit 2018: Care for Cancer","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/uppsala-health-summit-2018-care-cancer","search_api_id":"entity:node/96:en","date":"2018-06-14"},{"id":"97","entity_type":"node","label":"Drug Repurposing as a Source of Innovative Therapies in Pancreatic Cancer","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/drug-repurposing-source-innovative-therapies-pancreatic-cancer","search_api_id":"entity:node/97:en","date":"2018-06-14"},{"id":"98","entity_type":"node","label":"European Pancreatic Club Meeting 2018","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/european-pancreatic-club-meeting-2018","search_api_id":"entity:node/98:en","date":"2018-06-13"},{"id":"95","entity_type":"node","label":"ASCO Annual Meeting 2018","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/asco-annual-meeting-2018","search_api_id":"entity:node/95:en","date":"2018-06-04"},{"id":"94","entity_type":"node","label":"Drug Repurposing as a Source of Innovative Therapies in Osteosarcoma","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/drug-repurposing-source-innovative-therapies-osteosarcoma","search_api_id":"entity:node/94:en","date":"2018-06-02"},{"id":"91","entity_type":"node","label":"Annual Impact Sheet 2017","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/annual-impact-sheet-2017","search_api_id":"entity:node/91:en","date":"2018-04-19"},{"id":"101","entity_type":"node","label":"ReDO: selective PDE5 inhibitors as anti-cancer agents","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/redo-selective-pde5-inhibitors-anti-cancer-agents","search_api_id":"entity:node/101:en","date":"2018-04-11"},{"id":"100","entity_type":"node","label":"11th European Breast Cancer Conference","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/11th-european-breast-cancer-conference","search_api_id":"entity:node/100:en","date":"2018-03-21"},{"id":"99","entity_type":"node","label":"Repurposing non-cancer drugs for breast cancer? An emerging opportunity.","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/repurposing-non-cancer-drugs-breast-cancer-emerging-opportunity","search_api_id":"entity:node/99:en","date":"2018-03-21"},{"id":"238","entity_type":"node","label":"Cancer groundshot: going global before going to the moon","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/cancer-groundshot-going-global-going-moon","search_api_id":"entity:node/238:en","date":"2018-03-18"},{"id":"85","entity_type":"node","label":"European Training School in Perioperative Care of the Cancer Patient","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/european-training-school-perioperative-care-cancer-patient","search_api_id":"entity:node/85:en","date":"2018-03-09"},{"id":"83","entity_type":"node","label":"Roundtable at the European Parliament","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/roundtable-european-parliament","search_api_id":"entity:node/83:en","date":"2018-02-27"},{"id":"89","entity_type":"node","label":"ASPIRINE ALS BEHANDELING TEGEN DARMKANKER - patiëntonderzoek in Vlaanderen van start","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/aspirine-als-behandeling-tegen-darmkanker-patientonderzoek-vlaanderen-van-start","search_api_id":"entity:node/89:en","date":"2018-02-27"},{"id":"82","entity_type":"node","label":"Announcement on the ASPIRIN trial","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/announcement-aspirin-trial","search_api_id":"entity:node/82:en","date":"2018-01-10"},{"id":"61","entity_type":"node","label":"Brand-new patient-focussed website coming up in 2018","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/brand-new-patient-focussed-website-coming-2018","search_api_id":"entity:node/61:en","date":"2017-12-20"},{"id":"59","entity_type":"node","label":"SAVE THE DATE - roundtable on drug repurposing at European Parliament","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/save-date-roundtable-drug-repurposing-european-parliament","search_api_id":"entity:node/59:en","date":"2017-12-19"},{"id":"86","entity_type":"node","label":"Leaflet about the Anticancer Fund","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/leaflet-about-anticancer-fund","search_api_id":"entity:node/86:en","date":"2017-12-01"},{"id":"77","entity_type":"node","label":"ReDO: (hydroxy)chloroquine as anti-cancer agents","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/redo-hydroxychloroquine-anti-cancer-agents","search_api_id":"entity:node/77:en","date":"2017-11-23"},{"id":"60","entity_type":"node","label":"Our own Lydie Meheus wins the Gabrielle Moortgat Award","bundle":"news","langcode":"en","url":"https://www.anticancerfund.org/en/news/our-own-lydie-meheus-wins-gabrielle-moortgat-award","search_api_id":"entity:node/60:en","date":"2017-11-17"}]}